动态增强MRI对乳腺癌生物学行为评价
|
摘要
第一部分MR影像报告数据系统鉴别良恶性乳腺肿块的价值初探
目的评价美国放射学会的乳腺影像报告数据系统(BI-RADS)在动态增强MRI诊断乳腺癌中的价值,并分析动态增强参数最大增强线性斜率(S_(max))、最大流入曲线斜率(K_1)的意义。
方法81例疑似有乳腺肿块的患者术前做动态增强MRI检查(DCE-MRI),参照BI-RADS评分标准进行评分、分级;并计算动态增强参数S_(max)和K_1。
结果以手术病理结果为金标准,根据BI—RADS MR评分法:42例乳腺癌评为Ⅰ级1例,Ⅲ级6例,Ⅳ级12例,Ⅴ级的23例。39例良性占位评为Ⅰ级18例、Ⅱ级6例、Ⅲ级12例,Ⅳ级3例,Ⅴ级0例。两组间分级差异有统计学意义(x~2=50.649,P＜0.0001)。BI—RADS评分法(将Ⅳ级以上的病例定为恶性)诊断乳腺癌的敏感性、特异性、准确性、阳性预测值、阴性预测值分别为83.3%、92.9%、91.4%、92.1%、84.8%。结合BI—RADS评分法和动态增强参数的阈值诊断乳腺癌,与单纯BI—RADS法比较,两者差别无统计学意义(u=0.907,P=0.330)
结论BI—RADS评分法为乳腺癌的早期诊断制定了较规范、客观的诊断步骤和标准,结合动态增强参数S_(max)、K_1并不能提高良、恶性病变的鉴别诊断。
第二部分乳腺病变MRI动态增强参数与血管生成的相关性研究
目的探讨乳腺良、恶性病变MR动态增强(DCE)参数与肿瘤血管生成的关系。方法对51例乳腺良、恶性病变患者行前瞻性DCE-MR检查,计算动态增强参数:最大增强线性斜率(S_(max))、增强峰值(PH)、峰值时间(T_(peak))。所有病例手术病理标本行免疫组化染色,测定微血管密度(MVD)计数和血管内皮生长因子(VEGF)表达,分析各动态增强参数与乳腺癌MVD和VEGF表达的相关性。并比较29例乳腺癌与12例乳腺纤维腺瘤、10例乳腺病、10例癌旁正常组织MVD计数和VEGF表达的差别。
结果乳腺癌S_(max)(2.04±1.8)(r=0.807,P＜0.001)、PH(678±260)(r=0.697,p＜0.001)与MVD呈正相关,T_(peak)(69±38)与MVD呈负相关(r=-0.425,p＜0.05)。乳腺癌组MVD计数[(65.09±15.81)个/200倍视野]明显高于纤维腺瘤组、乳腺腺病组及癌旁正常组织组(p值分别为0.043、0.018、0.002)。69%(20/29)乳腺癌VEGF表达阳性,也明显高于其余各组(p值分别为0.035、0.007、0.001)。乳腺癌边缘区域的MVD(60.38±24.14)高于中央区域(37.64±16.52)(t=2.635,P=0.016)。腋窝淋巴结转移组的MVD(73.23±23.02)高于无转移组(59.34±18.03)(t=2.303,p=0.031)。
结论乳腺癌部分DCE-MR参数与MVD、VEGF相关,能较客观地反映乳腺癌血管生成状况,其MVD计数和VEGF表达明显高于乳腺良性病变及癌旁正常组织。
第三部分乳腺癌MR动态增强参数与预后因子的相关性研究
目的通过分析乳腺癌MR动态增强(DCE-MRI)形态学特征、动态增强参数与分子预后因子的相关性,探讨DCE-MRI活体评估乳腺癌预后的可行性。
方法对34例乳腺癌患者术前行DCE-MRI检查,病理组织免疫组化染色记录分子预后因子ER、Ki-67、c-erbB-2、uPA/PAI-1的表达情况,用Spearman等级相关分析法探讨乳腺癌DCE-MRI形态学特征、时间信号强度曲线、动态增强参数(强化率、峰值时间、初始斜率、流出率)与预后因子的相关性。
结果肿瘤毛刺状边缘与uPA/PAI-1阳性表达呈正相关(r=0.510),内部强化均匀性与ER表达情况呈负相关(r=-0.332),环形强化与淋巴结转移(r=0.560)、肿瘤病理学分级(r=0.354)、uPA/PAI-1阳性表达(r=0.314)呈正相关,与ER阳性表达呈负相关(r=-0.407),内部间隔情况与病理学分型(r=-0.684)、uPA/PAI-1阳性表达(r=-0.370)呈负相关。廓清型TIC曲线与uPA/PAI-1阳性表达呈正相关(r=0.507);峰值时间与ER阳性表达呈正相关(r=0.532),与Ki-67(r=-0.542)、c-erbB-2(r=-0.535)、uPA/PAI-1(r=-0.640)阳性表达呈负相关。
结论DCE-MRI不仅在乳腺肿瘤的定性诊断中起着重要作用,还可以间接预测肿瘤的预后,有潜在指导制定临床治疗方案的价值。其形态学特征和部分动态增强参数还与分子预后因子间存在相关性,肿瘤不均匀强化、环状强化、毛刺状边缘和动态增强短峰值时间、廓清型TIC常提示预后不良。
partⅠEvaluation of BI-RADS category in the diagnosis of breast masses with dynamic contrast enhanced MRI.
Objective:To evaluate the role of the breast imaging reporting and dada system (BI-RADS) categories developed by American College of Radiology and some parameters such as S_(mak)、K_1 in the diagnosis of breast masses with dynamic contrast enhanced magnetic resonance imaging(DCE-MRI)
Methods:Eighty-one patients with suspected breast mass underwent preoperative DCE-MRI of the breast.The MR images were divided into five categories according to BI-RADS criteria(categoryⅠ,negative;categoryⅡ,benign;categoryⅢ,probably benign; categoryⅣ,suspicious for malignancy;categoryⅤ,highly suggestive of malignancy). The parameters such as steepest slope(S_(max));wash-in slope(K_1) were calculated based on time-signal intensity curves of DCE-MRI.
Results:Pathologic findings were conducted as golden standard.Of 42 breast cancers,1, 0,6,12,23 cases were assigned to categoryⅠ,categoryⅡ,categoryⅢ,categoryⅣ, categoryⅤ,respectively.Of 39 benign lesions,18,6,12,3,0 cases were assigned to categoryⅠ,categoryⅡ,categoryⅢ,categoryⅣ,categoryⅤ,respectively.A significant difference was found between malignant and benign breast masses(x~2= 50.649,P＜0.0001).The sensitivity,specificity,accuracy rate,positive and negative predictive values of DCE-MRI according to BI-RADS(if category aboveⅣwere classified as malignant) were 83.3%、92.9%、91.4%、92.1%,84.8%,respectively.No significant difference between BI-RADS and BI-RADS combined with dynamic parameters was found in the diagnosis of breast cancer(u=0.907,P=0.330).
Conclusion:BI-RADS category is a standard and objective criterion for DCE-MRI in the diagnosis of breast cancer.However,dynamic parameters such as S_(max),K_1 aren't more helpful to the BI-RADS category in the differential diagnosis.
PartⅡCorrelative study of the parameters of dynamic contrast- enbanced MRI and angiogenesis in breast lesions
Objective To evaluate the relationship between dynamic contrast-enhanced MRI (DCE-MRI)-derived parameters and tumor angiogenesis in malignant and benign breast lesions.
Methods Fifty-one patients with malignant and benign breast diseases underwent DCE-MRI using Philips Intera 1.5 T MR system and dedicated breast coil prospectively before operation.DCE-MRI derived parameters such as steepest slope(S_(max)),peak height(PH),time-to-peak(T_(peak)) were calculated based on time-signal intensity curve.The micro-vessel density(MVD) was counted and vascular endothelial growth factor(VEGF) expression was assessed in these patients after operation with immunohistochemical staining method.The parameters were correlated statistically with MVD counts and VEGF expression in breast cancer.The MVD counts and VEGF expression were also compared among the patients with breast cancer(29 case),with fibroadenoma(12 case),mastopathy (10 case) and the normal tissue(10 case) beside the cancer.
Results The enhancement parameters S_(max)(r=0.807,p＜0.001)、PH(r=0.697,p＜0.001) correlated positively with MVD respectively.T_(peak)(69±38) correlated negatively with MVD counts(r=-0.425,P＜0.05).The mean value of MVD(65.09±15.81/200 times field) in patients with breast cancer were significantly more than those with fibroadenoma,mastopathy and the normal tissue beside the cancer,respectively(p= 0.043,p=0.018,P=0.002).69%(20/29)cases of breast cancers demonstrated positive VEGF expression,which were significantly more than the cases of fibroadenoma, mastopathy and the normal tissue beside the cancer(p=0.035,p=0.007,p= 0.001),respectively.Moreover,the MVD counts(60.38±24.14) at the peripheral region of breast cancer were more than those at central region(37.64±16.52)(t=2.635,p=0.016). There was a significant difference in MVD counts between breast cancers(73.23±23.02) with metastasis to axillary lymph nodes and those without metastasis(59.34±18.03)(t= 2.303,p=0.031).
Conclusion Some parameters derived from DCE-MRI correlated positively with MVD counts and VEGF expression in patients with breast cancer,which can reflect tumor angiogenesis objectively.The MVD counts and VEGF expression in patients with breast cancer were significantly more than those in patients with benign lesions.
PartⅢCorrelation of the parameters of dynamic contrast- enhanced MRI with prognostic factors in breast cancer
Objective To explore the possibility of dynamic contrast-enhanced MR imaging (DCE-MRI) in predicting the prognosis of breast cancer in vivo by correlating its morphological characteristics,the kinetic MR parameters on DCE-MRI with classical and molecular prognostic factors.
Methods Thirty-four patients with breast cancer underwent dynamic contrast-enhanced MR imaging before operation.The morphological characteristics on DCE-MRI,the type of time signal-intensity curve(TIC) and the kinetic enhancing parameters(enhancement ratio, E_(1-6);time to peak,T_(peak);the initial slope,Slope_i and the washout ratio,W_(peak-6)) were recorded.The correlation between them and detected biomarkers(ER,c-erbB-2,Ki-67, uPA/PAI-1),were statistically analyzed with the Spearman Rank Correlation.
Results The spicular enhancing periphery of the tumor correlated positively with the the expression of uPA/PAI-1(r=0.510).The internal homogenous enhancemant correlated negatively with the expression of ER(r=-0.332).The ring-like enhancement correlated positively with the metastases to lymph node(r=0.560),the pathological grade(r=0.354), the expression of uPA/PAI-1(r=0.314) and negatively with the expression of ER(r= -0.407).The wash-out type of TIC correlated positively with the expression of uPA/PAI-1 (r=0.507).The T_(peak) correlated negatively with the expression of Ki-67(r=-0.542), c-erbB-2(r=-0.535) and uPA/PAI-1(r=-0.640).It also correlated positively with the expression of ER(r=0.532).
Conclusion DCE-MRI play not only a important role in the differential diagnosis of breast cancer,but also is indirectly helpful in vivo both in evaluating the prognosis and in drawing up the treatment plan of the breast carcinoma.The statistical significant correlation between morphological characteristics,some kinetic enhancing parameters on DCE-MRI and detected biomarkers was found.The internal inhomogenous enhancemant, ring-like enhancement,spicular enhancing periphery of the tumor and short time to peak, washing out TIC are suggestive of unhealthy prognostic factors.
目的评价美国放射学会的乳腺影像报告数据系统(BI-RADS)在动态增强MRI诊断乳腺癌中的价值,并分析动态增强参数最大增强线性斜率(S_(max))、最大流入曲线斜率(K_1)的意义。
方法81例疑似有乳腺肿块的患者术前做动态增强MRI检查(DCE-MRI),参照BI-RADS评分标准进行评分、分级;并计算动态增强参数S_(max)和K_1。
结果以手术病理结果为金标准,根据BI—RADS MR评分法:42例乳腺癌评为Ⅰ级1例,Ⅲ级6例,Ⅳ级12例,Ⅴ级的23例。39例良性占位评为Ⅰ级18例、Ⅱ级6例、Ⅲ级12例,Ⅳ级3例,Ⅴ级0例。两组间分级差异有统计学意义(x~2=50.649,P＜0.0001)。BI—RADS评分法(将Ⅳ级以上的病例定为恶性)诊断乳腺癌的敏感性、特异性、准确性、阳性预测值、阴性预测值分别为83.3%、92.9%、91.4%、92.1%、84.8%。结合BI—RADS评分法和动态增强参数的阈值诊断乳腺癌,与单纯BI—RADS法比较,两者差别无统计学意义(u=0.907,P=0.330)
结论BI—RADS评分法为乳腺癌的早期诊断制定了较规范、客观的诊断步骤和标准,结合动态增强参数S_(max)、K_1并不能提高良、恶性病变的鉴别诊断。
第二部分乳腺病变MRI动态增强参数与血管生成的相关性研究
目的探讨乳腺良、恶性病变MR动态增强(DCE)参数与肿瘤血管生成的关系。方法对51例乳腺良、恶性病变患者行前瞻性DCE-MR检查,计算动态增强参数:最大增强线性斜率(S_(max))、增强峰值(PH)、峰值时间(T_(peak))。所有病例手术病理标本行免疫组化染色,测定微血管密度(MVD)计数和血管内皮生长因子(VEGF)表达,分析各动态增强参数与乳腺癌MVD和VEGF表达的相关性。并比较29例乳腺癌与12例乳腺纤维腺瘤、10例乳腺病、10例癌旁正常组织MVD计数和VEGF表达的差别。
结果乳腺癌S_(max)(2.04±1.8)(r=0.807,P＜0.001)、PH(678±260)(r=0.697,p＜0.001)与MVD呈正相关,T_(peak)(69±38)与MVD呈负相关(r=-0.425,p＜0.05)。乳腺癌组MVD计数[(65.09±15.81)个/200倍视野]明显高于纤维腺瘤组、乳腺腺病组及癌旁正常组织组(p值分别为0.043、0.018、0.002)。69%(20/29)乳腺癌VEGF表达阳性,也明显高于其余各组(p值分别为0.035、0.007、0.001)。乳腺癌边缘区域的MVD(60.38±24.14)高于中央区域(37.64±16.52)(t=2.635,P=0.016)。腋窝淋巴结转移组的MVD(73.23±23.02)高于无转移组(59.34±18.03)(t=2.303,p=0.031)。
结论乳腺癌部分DCE-MR参数与MVD、VEGF相关,能较客观地反映乳腺癌血管生成状况,其MVD计数和VEGF表达明显高于乳腺良性病变及癌旁正常组织。
第三部分乳腺癌MR动态增强参数与预后因子的相关性研究
目的通过分析乳腺癌MR动态增强(DCE-MRI)形态学特征、动态增强参数与分子预后因子的相关性,探讨DCE-MRI活体评估乳腺癌预后的可行性。
方法对34例乳腺癌患者术前行DCE-MRI检查,病理组织免疫组化染色记录分子预后因子ER、Ki-67、c-erbB-2、uPA/PAI-1的表达情况,用Spearman等级相关分析法探讨乳腺癌DCE-MRI形态学特征、时间信号强度曲线、动态增强参数(强化率、峰值时间、初始斜率、流出率)与预后因子的相关性。
结果肿瘤毛刺状边缘与uPA/PAI-1阳性表达呈正相关(r=0.510),内部强化均匀性与ER表达情况呈负相关(r=-0.332),环形强化与淋巴结转移(r=0.560)、肿瘤病理学分级(r=0.354)、uPA/PAI-1阳性表达(r=0.314)呈正相关,与ER阳性表达呈负相关(r=-0.407),内部间隔情况与病理学分型(r=-0.684)、uPA/PAI-1阳性表达(r=-0.370)呈负相关。廓清型TIC曲线与uPA/PAI-1阳性表达呈正相关(r=0.507);峰值时间与ER阳性表达呈正相关(r=0.532),与Ki-67(r=-0.542)、c-erbB-2(r=-0.535)、uPA/PAI-1(r=-0.640)阳性表达呈负相关。
结论DCE-MRI不仅在乳腺肿瘤的定性诊断中起着重要作用,还可以间接预测肿瘤的预后,有潜在指导制定临床治疗方案的价值。其形态学特征和部分动态增强参数还与分子预后因子间存在相关性,肿瘤不均匀强化、环状强化、毛刺状边缘和动态增强短峰值时间、廓清型TIC常提示预后不良。
partⅠEvaluation of BI-RADS category in the diagnosis of breast masses with dynamic contrast enhanced MRI.
Objective:To evaluate the role of the breast imaging reporting and dada system (BI-RADS) categories developed by American College of Radiology and some parameters such as S_(mak)、K_1 in the diagnosis of breast masses with dynamic contrast enhanced magnetic resonance imaging(DCE-MRI)
Methods:Eighty-one patients with suspected breast mass underwent preoperative DCE-MRI of the breast.The MR images were divided into five categories according to BI-RADS criteria(categoryⅠ,negative;categoryⅡ,benign;categoryⅢ,probably benign; categoryⅣ,suspicious for malignancy;categoryⅤ,highly suggestive of malignancy). The parameters such as steepest slope(S_(max));wash-in slope(K_1) were calculated based on time-signal intensity curves of DCE-MRI.
Results:Pathologic findings were conducted as golden standard.Of 42 breast cancers,1, 0,6,12,23 cases were assigned to categoryⅠ,categoryⅡ,categoryⅢ,categoryⅣ, categoryⅤ,respectively.Of 39 benign lesions,18,6,12,3,0 cases were assigned to categoryⅠ,categoryⅡ,categoryⅢ,categoryⅣ,categoryⅤ,respectively.A significant difference was found between malignant and benign breast masses(x~2= 50.649,P＜0.0001).The sensitivity,specificity,accuracy rate,positive and negative predictive values of DCE-MRI according to BI-RADS(if category aboveⅣwere classified as malignant) were 83.3%、92.9%、91.4%、92.1%,84.8%,respectively.No significant difference between BI-RADS and BI-RADS combined with dynamic parameters was found in the diagnosis of breast cancer(u=0.907,P=0.330).
Conclusion:BI-RADS category is a standard and objective criterion for DCE-MRI in the diagnosis of breast cancer.However,dynamic parameters such as S_(max),K_1 aren't more helpful to the BI-RADS category in the differential diagnosis.
PartⅡCorrelative study of the parameters of dynamic contrast- enbanced MRI and angiogenesis in breast lesions
Objective To evaluate the relationship between dynamic contrast-enhanced MRI (DCE-MRI)-derived parameters and tumor angiogenesis in malignant and benign breast lesions.
Methods Fifty-one patients with malignant and benign breast diseases underwent DCE-MRI using Philips Intera 1.5 T MR system and dedicated breast coil prospectively before operation.DCE-MRI derived parameters such as steepest slope(S_(max)),peak height(PH),time-to-peak(T_(peak)) were calculated based on time-signal intensity curve.The micro-vessel density(MVD) was counted and vascular endothelial growth factor(VEGF) expression was assessed in these patients after operation with immunohistochemical staining method.The parameters were correlated statistically with MVD counts and VEGF expression in breast cancer.The MVD counts and VEGF expression were also compared among the patients with breast cancer(29 case),with fibroadenoma(12 case),mastopathy (10 case) and the normal tissue(10 case) beside the cancer.
Results The enhancement parameters S_(max)(r=0.807,p＜0.001)、PH(r=0.697,p＜0.001) correlated positively with MVD respectively.T_(peak)(69±38) correlated negatively with MVD counts(r=-0.425,P＜0.05).The mean value of MVD(65.09±15.81/200 times field) in patients with breast cancer were significantly more than those with fibroadenoma,mastopathy and the normal tissue beside the cancer,respectively(p= 0.043,p=0.018,P=0.002).69%(20/29)cases of breast cancers demonstrated positive VEGF expression,which were significantly more than the cases of fibroadenoma, mastopathy and the normal tissue beside the cancer(p=0.035,p=0.007,p= 0.001),respectively.Moreover,the MVD counts(60.38±24.14) at the peripheral region of breast cancer were more than those at central region(37.64±16.52)(t=2.635,p=0.016). There was a significant difference in MVD counts between breast cancers(73.23±23.02) with metastasis to axillary lymph nodes and those without metastasis(59.34±18.03)(t= 2.303,p=0.031).
Conclusion Some parameters derived from DCE-MRI correlated positively with MVD counts and VEGF expression in patients with breast cancer,which can reflect tumor angiogenesis objectively.The MVD counts and VEGF expression in patients with breast cancer were significantly more than those in patients with benign lesions.
PartⅢCorrelation of the parameters of dynamic contrast- enhanced MRI with prognostic factors in breast cancer
Objective To explore the possibility of dynamic contrast-enhanced MR imaging (DCE-MRI) in predicting the prognosis of breast cancer in vivo by correlating its morphological characteristics,the kinetic MR parameters on DCE-MRI with classical and molecular prognostic factors.
Methods Thirty-four patients with breast cancer underwent dynamic contrast-enhanced MR imaging before operation.The morphological characteristics on DCE-MRI,the type of time signal-intensity curve(TIC) and the kinetic enhancing parameters(enhancement ratio, E_(1-6);time to peak,T_(peak);the initial slope,Slope_i and the washout ratio,W_(peak-6)) were recorded.The correlation between them and detected biomarkers(ER,c-erbB-2,Ki-67, uPA/PAI-1),were statistically analyzed with the Spearman Rank Correlation.
Results The spicular enhancing periphery of the tumor correlated positively with the the expression of uPA/PAI-1(r=0.510).The internal homogenous enhancemant correlated negatively with the expression of ER(r=-0.332).The ring-like enhancement correlated positively with the metastases to lymph node(r=0.560),the pathological grade(r=0.354), the expression of uPA/PAI-1(r=0.314) and negatively with the expression of ER(r= -0.407).The wash-out type of TIC correlated positively with the expression of uPA/PAI-1 (r=0.507).The T_(peak) correlated negatively with the expression of Ki-67(r=-0.542), c-erbB-2(r=-0.535) and uPA/PAI-1(r=-0.640).It also correlated positively with the expression of ER(r=0.532).
Conclusion DCE-MRI play not only a important role in the differential diagnosis of breast cancer,but also is indirectly helpful in vivo both in evaluating the prognosis and in drawing up the treatment plan of the breast carcinoma.The statistical significant correlation between morphological characteristics,some kinetic enhancing parameters on DCE-MRI and detected biomarkers was found.The internal inhomogenous enhancemant, ring-like enhancement,spicular enhancing periphery of the tumor and short time to peak, washing out TIC are suggestive of unhealthy prognostic factors.
引文
1 健康新视野。乳腺癌的九个错误理解 [EB/OL]. [2007-07-10]. http://disease.39.net/carcinoma/bk/rxa/254088.html.
2 Suzuki T, Toi M, Saji S, et al. Early breast cancer. Int J Clin Oncol. 2006 Apr; 11(2): 108-19
3 Agnese DM. Advances in breast imaging. Surg Technol Int. 2005; 14:51-6.
4 Meisamy S, Bolan PJ, Baker EH et al. Adding in Vivo Quantitative 1H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary Results of Observer Performance Study at 4.0 T. Radiology 2005;236:465-475.
5 Duric N, Littrup P, Poulo L et al. Detection of breast cancer with ultrasound tomography: first results with the Computed Ultrasound Risk Evaluation (CURE) prototype. Med Phys. 2007;34(2):773-85.
6 Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005 Nov 20;23(33):8469-76.
7 Chung A, Saouaf R, Scharre K, et al. The impact of MRI on the treatment of DCIS. Am Surg. 2005 Sep;71(9):705-10.
8 Echevarria JJ, Martin M, Saiz A, et al. Overall breast density in MR mammography: diagnostic and therapeutic implications in breast cancer. J Comput Assist Tomogr. 2006;30(1):140-7.9
9 Kvistad KA, Radland J, Vainio J, et al. Breast lesions: Evaluation with dynamic contrast enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging. Radiology 2000, 216:545-55310
10 Teifke A, Behr O, Schmidt M et al. Dynamic MR Imaging of Breast Lesions: Correlation with Microvessel Distribution Pattern and Histologic Characteristics of Prognosis. Radiology. 2006 ;239(2):351-60.
11 Hagen AI, Kvistad KA, Maehle L et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast, 2007 16(4):367-74
12 Cilotti A, Iacconi C, Marini C et al. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications. Radiol Med (Torino). 2007;112(2):272-86.
13 Khatri VP, Stuppino JJ ,Espinosa MH ,et al. A simple improved magnetic resonance imaging method [J]. Cancer,2001, 92: 471-478.
14 Teifke A,Hlawatsch A,Beier T,et al.Undetected Malignancies of the Breast:Dynamic Contrast-enhanced MR Imaging at 1.0 T.Radiology 2002;224:881-888.
15 American College of Radiology(ACR).Illustrated breast imaging reporting and dada system(BI-RADS),3nd ed.Reston.VA:American College of Radiology.1998.
16 Weinder H,Folkman,Pozza F,et al.Tumor angiogenesis:a new significant and independent progrostic indicator in early-stage breast carcinoma.I Natl Cancer Inst.1992,84(24):1875-1887.
17 Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma.Nengl J Med,1991,324(1):1-8.
18.Lantzsch T,Hefler L,Krause U,et al.The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.Anticancer Res,2002,22(3):1925-1928.
19.Kolch W,Martiny-Baron G,Kieser A,et al.Regulation of the expression of the VEGF/VPS and its receptors:role in tumor angiogenesis.Breast Cancer Res Treat,1995,36(2):139-155.
20.Carriero A,Ambrossini R,Mattei PA,et al.Magnetic resonance of the breast:correlation between enhancement patterns and microvessel density in malignant tumors.J Exp Clin Cancer Res,2002,21(3Suppl):83-87.PMID:12585660
21 陈蓉,龚水根,张伟国等.乳腺癌MRI形态学表现与病理、分了生物学相关性研究.中华放射学杂志,2004,38:620-625.
22 Francisco JE,Gabriel NH.Prognostic molecular markers in early breast cancer.Breast Cancer Res,2004,6(3):109-118.
23 Keshgegian AA,Cnaan A.Proliferation markers in breast carcinoma.Mitotic figure count,S-phase fraction,proliferating cell nuclear antigen,Ki-67 and MIB-1.Am J Clin Pathol,1995,104(1):42-49.
24 Weigelt B,Peterse JL,van't Veer LJ.Breast cancer metastasis:markers and models.Nat Rev Cancer,2005,5(8):591-602.
1.Breast imaging reporting and dada system(BI-RADS-MRI)(first edition).American College of Radiology.2003,98..
2.Fischerostic utility of tumor vascularity on magnetic resonance imaging of the breast.J Magn Reson Imaging,2000,18:807-813.
5.Kuhl CK.MRI of breast tumor.Eur Radio U.Lehratlas der MR-Mammographie.Stuttgart.Germany:Thieme.2000:24-31
3.刘玉品,杨小庆。磁共振检查在乳腺肿瘤临床应用的相关进展.东南大学学报,2003,22(5):353-357.
4.Yoko A,Hiroshi F,Tsuneo I,et al.Diagn 1,2000,10(1):46-58.
6.Fisher ER,Gregorio R.Redmond C,Vellios F,Sommers SC.Fisher B.Pathologic findings from the National Surgical Adjuvant Breast Project(Protocol no.4).1,Observations concerning the multicentricity of mammary cancer.Cancer,1975,35:247-254.
7.Liu PF,Debatin JF,Caduff RF,Kacl G,et al.Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis.Br J Radiol,1998,71:501-509.
8.Thomas H.Helbich,et al.Contrast-enhanced magnetic resonance imaging of the breast.Eur Radiol,2000,34:208-219.
9.Nunes LW,Schnall MD,Siegelman ES,et al.Diagnostic performance charac—teristics of architectural features revealed by high spatial resolution MR imaging of the breast[J].Am J Roentgenol,1997,169(3):409-415.
10.Roka M,Yoshitomo M,Genichiro E,et al.Breast masses with peripheral rim enhancement on dynamic contrast—enhanced MR images:correlation of MR findings with histologic features and expression of growth factors[J].Radiology,2000,217(3):841-848.
11.Szabo BK,Aspelin P,Kristoffersen Wiberg M,et al.Invasive breast cancer:correlation of dynamic MR features with prognostic factors.Eur Radiol 2003;13(11):2425-2435.
12.Susan PW,SG Orel,Rose Heller,et al.MR Imaging of the Breast in Patients with Invasive Lobular Carcinoma.Am.J.Roentgenol,2001,176(2):399-406.
13.Nunes LW,Schnall MD,Orel SG,et al.Correlation of lesion appearance and histologic findings for the nodes of a breast MR imaging interpretation model.Radiographics,1999,19:79-92.
14.Liotta LA,Stetler-Stevenson WG.Tumor invasion and metastasis:an imbalance of positive and negative regulation.Cancer Res,1991,51(18 Suppl):5054-5059.
15.J Brown,D Buckley,A Coulthard,et al.Magnetic resonance imaging screening in women at genetic risk of breast cancer:imaging and analysis protocol for the UK multicentre study.Magn Reson Imaging,Sep 2000;18(7):765-776.
16.Kvistad KA,Rydland J,Vainio J,et al.Breast lesions:evaluation with dynamic contrast enhanced T1-weighted MR imaging and with T2~*-weighted first pass perfusion MR imaging[J].Radiology,2000,216(2):545-553.
17.Kuhl CK,Mielcareck P,Klaschik S,et al.Dynamic breast MR imaging:are signal intensity time course data useful for differential diagnosis of enhancing lesions?[J]Radiology,1999,211(1):101-110.
18.Thomas H,Helbich,et al.Contrast-enhanced magnetic resonance imaging of the breast.Eur Radiol,2000,34:208-219.
19.Buadu LD,Murakami J,Murayama S,et al.(1996) Breast lesions:correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis.Radiology 2000:639-649.
20.Daniel BL,Yen YF,Glover GH,et al.Breast disease:dynamic spiral MR imaging Radiology,1998,209(11):499-509.
21.刘勇,汤光宇,顾伟中,等.动态增强MR对乳腺癌血管生成的评价.国外医学 临床放射学分册,2005,28(6):41.-416.
22.Gokalp G,Topal U,et al.MR imaging in probably benign lesions(BI-RADS category 3) of the breast.Eur J Radiol.2006,57(3):436-44.
23.Baum F,Fischer U,Vosshenrich R,et al.Classification of hypervascularized lesions in CE MR imaging of the breast.Eur Radiol,2002;12(5):1087-92.
24.Katja C.Siegmann,Markus Muller-Schimpfle,Fritz Schick,et al.MR Imaging—Detected Breast Lesions:Histopathologic Correlation of Lesion Characteristics and Signal Intensity Data.A JR.2002,178:1403-1409.
1 Carriero A,Ambrossini R,Mattei PA,et al.Magnetic resonance of the breast:correlation between enhancement patterns and microvessel density in malignant tumors.J Exp Clin Cancer Res,2002,21(3 Suppl):83-87.
2 Bymes K,White S,Chu Q,et al.High eIF4E,VEGF,and microvessel density in stage Ⅰ to Ⅲbreast cancer.Ann Surg,2006,243:684-692.
3 Oshida K,Nagashima T,Ueda T,et al.Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography.Eur Radiol,2005,15:1353-1360.
4 Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma.N Engl J Med,1991,324:1-8.
5 Mattern J,Koomagi R,Volm M.Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.Br J Cancer.1996,73:931-934.
6 Folkman J.Tumor angiogenesis:therapeutic implications.N Engi J Med,1971,285:1182—1186.PMID:4938153
7 Gasparini G.Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer.Oncologist,2000,5(Suppl 11):37-44.
8 王辅林,韦立真,陈乐新,等.血管内皮生长因子、微血管密度与乳腺癌腋窝淋巴结转移及预后的关系.中华病理学杂志,2000,29:172-175.
9 刘勇 汤光宇 顾伟中,等.动态增强MRI对乳腺癌血管生成的评价(综述).国外医学临床放射学分册,2005,28:413-416.
10 Stomper PC,Winston JS,Herman S,et al.Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions.Breast Cancer Res Treat,1997,45:39-46.
11 Teifke A,Behr O,Schmidt M,et al.Dynamic MR imaging of breast lesions:correlation with microvessel distribution pattern and histologic characteristics of prognosis.Radiology,2006,239:351-360.
12 Matsubayashi R,Mstsusuo Y,Edakuni G,et al.Breast Masses with Peripheral Rim Enhancement on Dynamic Contrast-enhanced MR Images:Correlation of MR Findings with Histoiogic Features and Expression of Growth Factors.Radiology,2000,217:841-848.
13 徐丽莹,孔祥泉,徐海波,等.乳腺癌动态增MRI边缘强化与病理特征及VEGF表达相关性.放射学实践,2004,19,291-294.
14 Li WW.Tumor angiogenesis:molecular pathology,therapeutic targeting,and imaging.Acad Radiol,2000,7:800-811.
15 邹煜 张敏鸣 王丽君,等.肺癌MRI动态增强模式与肿瘤血管生成的相关性研究.中华放射学杂志.2002,37,1150-1155.
16 Buadu LD,Murakami J,Murayama S,et al.Patterns of peripheral enhancement in breast masses:correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis.J Comput Assist Tomogr,1997,21:421-430.
17 Heywang-Kobrunner SH,Bick U,Bradley WG Jr,et al.International investigation of breast MRI:results of a multicentre study(11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions.Eur Radiol,2001,11:531-546.
18 Tofts PS,Brix G,Buckley DL,et al.Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer:standardized quantities and symbols.J Magn Reson Imaging,1999,10:223-232.
19 Tse GM,Chaiwun B,Wong KT,et al.Magnetic resonance imaging of breast lesions-a pathologic correlation.Breast Cancer Res Treat,2007,103:1-10.
1 陈蓉,龚水根,张伟国等.乳腺癌MRI形态学表现与病理、分子生物学相关性研究.中华放射学杂志,2004,38:620-625.
2 Tozaki M.Interpretation of breast MRI:correlation of kinetic and morphological parameters with pathological fingdings.Magnetic Resonance in Medical Sciences,2004,3:189-197.
3 Schnall MD,Rosten S,Englander S,et al.A combined architectural and kinetic interpretation model for breast MR images.Acad Radio,2001,8(7):591-597.
4 Kuhl CK,Mielcareck P,Klaschik S et al.Dynamic breast MR imaging:are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology,1999,211(1):101-110.
5 Stephen s.Steinberg主编,外科病理学,回允中主译。北京大学医学出版社,2006.1。Frierson HF,Jr,Wolber RA,Berean KW,et al.Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma.Am J Clin Pathol 1995;103(2):195-198.
7 Neubauer H,Mengxia LI,Kuehne HR,et al.High grade and nonhigh grade ductal carcinoma in situ on dynamic MR mamography:characteristic findings for signal increase and morphological pattern of enhancement.B r J Radiol,2003,76:3-12.
8 Teifke A,Lehr HA,Vomweg TW,et al.Outcome analysis and rational management of enhancing lesions incidentally detected on contrast enhanced MRI of the breast.AJR,2003,181(3):655-662.
9 LaTrenta LR,Jennifer H,Menell EA,et al.Breast lesions detected with MR imaging:utility and histopathologic importance of identification with US.Radiology,2003,22 7(3):856-861.
10 Teifke A,Alexander H,Thomas B,et al.Undetected malignancies of the breast:dynamic contrast-enhanced MR imaging at 1.0T.Radiology,2002,224(3):881-888.
11 Fischer U,KopkaL,GrabbeE,et al.Breast carcinoma:effect of preoperative contrast-enhanced MR imaging on the therapeutic approach.Radiology,1999,213(3):881-888.
12 Kneeshaw PI,TurnbullL W,Smith A,et al.Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer.EJSO,2003,29(1):32-37.
13 Rieber A,Katharina S,Gisela H,et al.Breast-conserving surgery and autogenous tissue reconstruction in patients with breast cancer:efficacy of MRI of the breast in the detection of recurrent disease.Eur Radiol,2003,13(4):780-787.
14 Morris EA,Liberman L,Douglas BJ,et al.MRI of occult breast carcinoma in a high-risk population. AJR, 2003,181(3):619-626.
15 Orel SG MR imaging of the breast. Radiol Clin North Am, 2000, 38(4):899-913.
16 Kuhl CK. MRI of breast tumor. Eur Radiol, 2000,10(1):46-58.
17 Esserman L, Hylton N, George T, et al. Contrast-enhanced Magnetic Resonance Imaging to assess Tumor Histopathology and Angiogenesis in Breast Carcinoma[J]. Breast J, 1999, 5(1): 13-21.
18 Carriero A, Ambrossini R, Mattei PA,et al. Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors. J Exp Clin Cancer Res, 2002, 21(3 Suppl):83-87.
19 Tuncbilek N, Unln E, Karakas HM, et al. Evaluation of tumor angiogenesis with contrast enhanced dynamic magnetic resonance mammography[J]. Breast J, 2003, 9(5):403-408.
20 Tynninen O, Boguslawski KV, Aronen HJ, et al. Prognostic value of vascular density and cell proliferation in breast cancer patients. Pathol Res Pract, 1999, 195:31-37.
21 Bando H, Weich HA, Brokelmann M, et al. Association between in tratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer, 2005, 92(3):553-61.
22 Francisco JE,Gabriel NH.Prognostic molecular markers in early breast cancer. Breast Cancer Res, 2004,6(3): 109-118.
23 Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol, 1995,104(1):42-49.
24 Paik S , Bryant J , Park C , et al .C-erbB-2 and response to doxorubicin in patients with axillary lymph node positive , hormone receptor negative breast cancer[J] . J Natl Cancer Inst, 1998 , 90 (18): 1361 - 1370.
25 Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer, 2005, 5(8):591-602.
26 Broet P, Spyratos F, Romain S, et al.Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. Br J Cancer, 1999,80(3-4):536-545.
27 Harbeck N,Kates RE,Schmitt M.Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol, 2002,20(4): 1000-1007.
28 Michael J. Duffy.Urokinase Plasminogen Activator and Its Inhibitor,PAl-l, as Prognostic Markers in Breast Cancer : From Pilot to Level 1 Evidence Studies. Clinical Chemistry, 2002,48(8): 1194-1197.
29 Stomper PC, Herman S, Klippenstein DL.Suspect breast lesions:findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology, 1995,197:387-395
30 Schnall MD.An overview of interpretation strategies for breast MR imaging. Magn Reson Imaging Clin Nam, 2001,9(2):289-294.
31 Nunes LW,SCHnall MD,Orel SG,et al.Breast MR imaging: interpretation model.Radiology, 1997,202(3):833-841.
32 Buadu LD,Murakami J,Murayama S,et al.Breast lesionsxorrelation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis.Radiology, 1996,200(3):639-649.
33 Buckley DL,Drew PJ,Mussurakis S,et al.Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI.J Magn Reson Imaging , 1997,7:461-464.
34 Matsubayashi R,Matsuo Y,Edakuni G, et al. Breast masses with peripheral rim enhancement on dynamic contrast enhanced MR images:correlation of MR findings with histologic features and expression of growth factors. Radiology ,2000,217(3):841-848.
35 Stamper PC, Herman S, Klippenstein DL,et al.Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer, 1996,77(9): 1844-1849.
36 Szabo BK, Aspelin P, Kristoffersen Wiberg M, et al.Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol, 2003,13(11):2425 - 2435.
37 Tuncbilek N, Karakas HM, Okten OO. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol, 2005,53 (2): 199-205.
38 Lamb PM,Perry NM,Vinnicombe SJ,et al.Correlation between ultrasound characteristics,mammographic findings and histological grade in patients with invasive ductal carcinoma of the breast.Clin Radio,2000,55:40-44
39 Fischer U, Kopka L, Brinck U, et al.Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol, 1997 ,7(7): 1002-1005.
40 Bone B, Aspelin P, Bronge L, et al. Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol, 1998 ,39:279-84.
41 Mussrakis S,Buckley DL,Horsman A. Dynamic MR imaging of invasive breast cancer: correlation with tumor grade and other histological factors. Br J Radiol, 1997,70(833): 445-46.
[42] 李明山,周玉荣,王丽等. 3D TIWI 动态增强成像诊断乳腺良恶性病变的价值. 中国临床医学影像杂志. 2005, 5 (16): 256-259
1. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res, 1991, 51(18 Suppl):5054-5059
2. Hulka CA, Edmister WB, Smith BL, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology, 1997,205(3): 837-842
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285(21):1182— 1186
4. Folkman J, Beckner K. Angiogenesis imaging. Acad Radiol, 2000,7( 10):783-785
5. Kolch W, Martiny-Baron G, Kieser A, et al. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat, 1995,36(2): 139-155
6. Kato T, Kimura T, Miyakawa R, et al. Clinicopathologic study of angiogenesis in Japanese patients with breast cancer. World J Surg, 1997,21(1):49-56
7. Orel SG. MR imaging of the breast. Radiol Clin North Am , 2000, 38:899-913.
8. Kuhl CK. MRI of breast tumor. Eur Radiol, 2000,10(1):46-58
9. Kuhl C, Mielcareck P, Klaschnik S, et al. Dynamik breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions. Radiology, 1999,211 (1) :101—110
10. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging,2003,18(4):467-477
11. Yoko Andoa, Hiroshi Fukatsua, Tsuneo Ishiguchia,et al. Diagnostic utility of tumor vascularity on magnetic resonance imaging of the breast. Magn Reson Imaging , 2000,18(7): 807-813
12. Stomper PC, Winston JS, Herman S, et al. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat, 1997, 45(1):39-46
13. Furuta A, Ishibashi T, Takahashi S, et al. Magnetic resonance imaging of breast cancer: correlation between contrast enhancement and tumor angiogenesis. Nippon Igaku Hoshasen Gakkai Zasshi,1999, 59(12):682-688
14. Furman-Haran E, Edna, Degani, et al. Parametric Analysis of Breast MRI. J Comput Assist Tomogr, 2002, 26(3):376-386
15. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1 -weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging, 1999, 10(3):223-232
16. Nagasima T,Suzuki M,Yagata H, et al. Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast cancer,2002, 9(3):226-230
17. Aref M, Brechbiel M, Wiener EC, et al. Identifying Tumor Vascular Permeability Heterogeneity With Magnetic Resonance Imaging Contrast Agents. Invest Radiol, 2002, 37(4): 178-192
18. Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging, 2004, 20(1):138-144
19. Daldrup-Link HE, Kaiser A, Helbich T, et al. Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. Acad Radiol, 2003, 10(11):1237-1246
20. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by alphaVbeta3- targeted magnetic resonance imaging. Nat Med, 1998,4: 623
1. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist,2004, 9(6): 606-616.
2. Jatoi I,Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol, 1999,17(8):2334-40.
3. Albertini JJ, Lyman GH, Cox C. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA, 1996,276(22): 1818-1822.
4. Chia SK, Speers CH, Bryce CJ, et al. Ten-Year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol,2004,22(9): 1630-1637.
5. Francisco JE,Gabriel NH. Prognostic molecular markers in early breast cancer. Breast Cancer Res, 2004,6(3): 109-118.
6. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol,1995,104(1):42-49.
7. Hilsenbeck SG, Ravdin PM, de Moor CA. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat, 1998,52(1-3):227 - 237.
8. Early Breast Cancer Trialists' Collaborative Group.Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 1998,351(9114): 1451 - 1467.
9. Harold J,Burstein. The distinctive nature of HER2-positive breast cancers. NEJM,2005, 353(16):1652-1654.
10. Schnall MD, Rosten S, Englander S,et al. A combined architectural and kinetic interpretation model for breast MR images. Acad Radiol ,2001,8(7):591 - 597.
11. Tuncbilek N,Karakas HM,Okten OO. MRI in multiple myeloma with orbitaland and dural invasion.Tumori,2005,91(3):270-272.
12. Szabo BK, Aspelin P, Kristoffersen Wiberg M,et al. Invasive breast cancer:correlation of dynamic MR features with prognostic factors.Eur Radiol, 2003,13(11):2425 - 2435.
13. Stomper PC, Herman S, Klippenstein DL, et al. Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer, 1996,77(9): 1844-1849.
14. Jinguji M, Kajiya Y, Kamimura K, et al. Rim enhancement of breast cancers on contrast-enhanced MR imaging: relationship with prognostic factors. Breast cancer (Tokyo, Japan) ,2006,13(1): 64-73.
15. Teifke A, Behr O, Schmidt M, et al. Dynamic MR Imaging of Breast Lesions: Correlation with Microvessel Distribution Pattern and Histologic Characteristics of Prognosis. Radiology 2006;239(2):351-360
16. Tozaki M.Interpretation of breast MRIxorrelation of kinetic and morphological parameters with pathological findings. Magn Reson Medi Sci ,2004,3(4): 189-197.
17. Kuhl CK, Mielcareck P, Klaschik S. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology, 1999,211(1): 101 - 110.
18. Tuncbilek N, Karakas HM, Okten OO. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol, 2005,53 (2): 199-205.
19. Komatsu S,Lee CJ, Ichikawa D et al. Predictive value of the time-intensity curves on dynamic contrast-enhanced magnetic resonance imaging for lymphatic spreading in breast cancer. Surg Today 2005,35(9): 720-724.
20. Mussrakis S, Buckley DL, Horsman A. Dynamic MR imaging of invasive breast cancerxorrelation with tumor grade and other histological factors. Br J Radiol ,1997,70(833): 446-45.
21. Mussrakis S, Buckley DL, Horsman A. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging. Radiology. 1997;203(2):317-21.
22. Bone B, Aspelin P, Bronge L, et al. Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol, 1998 ,39(3):279-84.
23. Stomper PC, Herman S, Klippenstein DL. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology, 1995,197(2):387-395
24. Fischer U, Kopka L, Brinck U, et al. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol ,1997 ,7(7): 1002-1005.
25. Kobayashi H, Kawamoto S. Sakai Y, et al. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst,2004,96(9):703-8.
26. Seenu V, Pavan Kumar MN, Sharma U, et al. Potential of magnetic resonance spectroscopy to detect metastasis in axillary lymph nodes in breast cancer. Magn Reson Imaging ,2005,23(10): 1005-1010.
2 Suzuki T, Toi M, Saji S, et al. Early breast cancer. Int J Clin Oncol. 2006 Apr; 11(2): 108-19
3 Agnese DM. Advances in breast imaging. Surg Technol Int. 2005; 14:51-6.
4 Meisamy S, Bolan PJ, Baker EH et al. Adding in Vivo Quantitative 1H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary Results of Observer Performance Study at 4.0 T. Radiology 2005;236:465-475.
5 Duric N, Littrup P, Poulo L et al. Detection of breast cancer with ultrasound tomography: first results with the Computed Ultrasound Risk Evaluation (CURE) prototype. Med Phys. 2007;34(2):773-85.
6 Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005 Nov 20;23(33):8469-76.
7 Chung A, Saouaf R, Scharre K, et al. The impact of MRI on the treatment of DCIS. Am Surg. 2005 Sep;71(9):705-10.
8 Echevarria JJ, Martin M, Saiz A, et al. Overall breast density in MR mammography: diagnostic and therapeutic implications in breast cancer. J Comput Assist Tomogr. 2006;30(1):140-7.9
9 Kvistad KA, Radland J, Vainio J, et al. Breast lesions: Evaluation with dynamic contrast enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging. Radiology 2000, 216:545-55310
10 Teifke A, Behr O, Schmidt M et al. Dynamic MR Imaging of Breast Lesions: Correlation with Microvessel Distribution Pattern and Histologic Characteristics of Prognosis. Radiology. 2006 ;239(2):351-60.
11 Hagen AI, Kvistad KA, Maehle L et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast, 2007 16(4):367-74
12 Cilotti A, Iacconi C, Marini C et al. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications. Radiol Med (Torino). 2007;112(2):272-86.
13 Khatri VP, Stuppino JJ ,Espinosa MH ,et al. A simple improved magnetic resonance imaging method [J]. Cancer,2001, 92: 471-478.
14 Teifke A,Hlawatsch A,Beier T,et al.Undetected Malignancies of the Breast:Dynamic Contrast-enhanced MR Imaging at 1.0 T.Radiology 2002;224:881-888.
15 American College of Radiology(ACR).Illustrated breast imaging reporting and dada system(BI-RADS),3nd ed.Reston.VA:American College of Radiology.1998.
16 Weinder H,Folkman,Pozza F,et al.Tumor angiogenesis:a new significant and independent progrostic indicator in early-stage breast carcinoma.I Natl Cancer Inst.1992,84(24):1875-1887.
17 Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma.Nengl J Med,1991,324(1):1-8.
18.Lantzsch T,Hefler L,Krause U,et al.The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.Anticancer Res,2002,22(3):1925-1928.
19.Kolch W,Martiny-Baron G,Kieser A,et al.Regulation of the expression of the VEGF/VPS and its receptors:role in tumor angiogenesis.Breast Cancer Res Treat,1995,36(2):139-155.
20.Carriero A,Ambrossini R,Mattei PA,et al.Magnetic resonance of the breast:correlation between enhancement patterns and microvessel density in malignant tumors.J Exp Clin Cancer Res,2002,21(3Suppl):83-87.PMID:12585660
21 陈蓉,龚水根,张伟国等.乳腺癌MRI形态学表现与病理、分了生物学相关性研究.中华放射学杂志,2004,38:620-625.
22 Francisco JE,Gabriel NH.Prognostic molecular markers in early breast cancer.Breast Cancer Res,2004,6(3):109-118.
23 Keshgegian AA,Cnaan A.Proliferation markers in breast carcinoma.Mitotic figure count,S-phase fraction,proliferating cell nuclear antigen,Ki-67 and MIB-1.Am J Clin Pathol,1995,104(1):42-49.
24 Weigelt B,Peterse JL,van't Veer LJ.Breast cancer metastasis:markers and models.Nat Rev Cancer,2005,5(8):591-602.
1.Breast imaging reporting and dada system(BI-RADS-MRI)(first edition).American College of Radiology.2003,98..
2.Fischerostic utility of tumor vascularity on magnetic resonance imaging of the breast.J Magn Reson Imaging,2000,18:807-813.
5.Kuhl CK.MRI of breast tumor.Eur Radio U.Lehratlas der MR-Mammographie.Stuttgart.Germany:Thieme.2000:24-31
3.刘玉品,杨小庆。磁共振检查在乳腺肿瘤临床应用的相关进展.东南大学学报,2003,22(5):353-357.
4.Yoko A,Hiroshi F,Tsuneo I,et al.Diagn 1,2000,10(1):46-58.
6.Fisher ER,Gregorio R.Redmond C,Vellios F,Sommers SC.Fisher B.Pathologic findings from the National Surgical Adjuvant Breast Project(Protocol no.4).1,Observations concerning the multicentricity of mammary cancer.Cancer,1975,35:247-254.
7.Liu PF,Debatin JF,Caduff RF,Kacl G,et al.Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis.Br J Radiol,1998,71:501-509.
8.Thomas H.Helbich,et al.Contrast-enhanced magnetic resonance imaging of the breast.Eur Radiol,2000,34:208-219.
9.Nunes LW,Schnall MD,Siegelman ES,et al.Diagnostic performance charac—teristics of architectural features revealed by high spatial resolution MR imaging of the breast[J].Am J Roentgenol,1997,169(3):409-415.
10.Roka M,Yoshitomo M,Genichiro E,et al.Breast masses with peripheral rim enhancement on dynamic contrast—enhanced MR images:correlation of MR findings with histologic features and expression of growth factors[J].Radiology,2000,217(3):841-848.
11.Szabo BK,Aspelin P,Kristoffersen Wiberg M,et al.Invasive breast cancer:correlation of dynamic MR features with prognostic factors.Eur Radiol 2003;13(11):2425-2435.
12.Susan PW,SG Orel,Rose Heller,et al.MR Imaging of the Breast in Patients with Invasive Lobular Carcinoma.Am.J.Roentgenol,2001,176(2):399-406.
13.Nunes LW,Schnall MD,Orel SG,et al.Correlation of lesion appearance and histologic findings for the nodes of a breast MR imaging interpretation model.Radiographics,1999,19:79-92.
14.Liotta LA,Stetler-Stevenson WG.Tumor invasion and metastasis:an imbalance of positive and negative regulation.Cancer Res,1991,51(18 Suppl):5054-5059.
15.J Brown,D Buckley,A Coulthard,et al.Magnetic resonance imaging screening in women at genetic risk of breast cancer:imaging and analysis protocol for the UK multicentre study.Magn Reson Imaging,Sep 2000;18(7):765-776.
16.Kvistad KA,Rydland J,Vainio J,et al.Breast lesions:evaluation with dynamic contrast enhanced T1-weighted MR imaging and with T2~*-weighted first pass perfusion MR imaging[J].Radiology,2000,216(2):545-553.
17.Kuhl CK,Mielcareck P,Klaschik S,et al.Dynamic breast MR imaging:are signal intensity time course data useful for differential diagnosis of enhancing lesions?[J]Radiology,1999,211(1):101-110.
18.Thomas H,Helbich,et al.Contrast-enhanced magnetic resonance imaging of the breast.Eur Radiol,2000,34:208-219.
19.Buadu LD,Murakami J,Murayama S,et al.(1996) Breast lesions:correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis.Radiology 2000:639-649.
20.Daniel BL,Yen YF,Glover GH,et al.Breast disease:dynamic spiral MR imaging Radiology,1998,209(11):499-509.
21.刘勇,汤光宇,顾伟中,等.动态增强MR对乳腺癌血管生成的评价.国外医学 临床放射学分册,2005,28(6):41.-416.
22.Gokalp G,Topal U,et al.MR imaging in probably benign lesions(BI-RADS category 3) of the breast.Eur J Radiol.2006,57(3):436-44.
23.Baum F,Fischer U,Vosshenrich R,et al.Classification of hypervascularized lesions in CE MR imaging of the breast.Eur Radiol,2002;12(5):1087-92.
24.Katja C.Siegmann,Markus Muller-Schimpfle,Fritz Schick,et al.MR Imaging—Detected Breast Lesions:Histopathologic Correlation of Lesion Characteristics and Signal Intensity Data.A JR.2002,178:1403-1409.
1 Carriero A,Ambrossini R,Mattei PA,et al.Magnetic resonance of the breast:correlation between enhancement patterns and microvessel density in malignant tumors.J Exp Clin Cancer Res,2002,21(3 Suppl):83-87.
2 Bymes K,White S,Chu Q,et al.High eIF4E,VEGF,and microvessel density in stage Ⅰ to Ⅲbreast cancer.Ann Surg,2006,243:684-692.
3 Oshida K,Nagashima T,Ueda T,et al.Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography.Eur Radiol,2005,15:1353-1360.
4 Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma.N Engl J Med,1991,324:1-8.
5 Mattern J,Koomagi R,Volm M.Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.Br J Cancer.1996,73:931-934.
6 Folkman J.Tumor angiogenesis:therapeutic implications.N Engi J Med,1971,285:1182—1186.PMID:4938153
7 Gasparini G.Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer.Oncologist,2000,5(Suppl 11):37-44.
8 王辅林,韦立真,陈乐新,等.血管内皮生长因子、微血管密度与乳腺癌腋窝淋巴结转移及预后的关系.中华病理学杂志,2000,29:172-175.
9 刘勇 汤光宇 顾伟中,等.动态增强MRI对乳腺癌血管生成的评价(综述).国外医学临床放射学分册,2005,28:413-416.
10 Stomper PC,Winston JS,Herman S,et al.Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions.Breast Cancer Res Treat,1997,45:39-46.
11 Teifke A,Behr O,Schmidt M,et al.Dynamic MR imaging of breast lesions:correlation with microvessel distribution pattern and histologic characteristics of prognosis.Radiology,2006,239:351-360.
12 Matsubayashi R,Mstsusuo Y,Edakuni G,et al.Breast Masses with Peripheral Rim Enhancement on Dynamic Contrast-enhanced MR Images:Correlation of MR Findings with Histoiogic Features and Expression of Growth Factors.Radiology,2000,217:841-848.
13 徐丽莹,孔祥泉,徐海波,等.乳腺癌动态增MRI边缘强化与病理特征及VEGF表达相关性.放射学实践,2004,19,291-294.
14 Li WW.Tumor angiogenesis:molecular pathology,therapeutic targeting,and imaging.Acad Radiol,2000,7:800-811.
15 邹煜 张敏鸣 王丽君,等.肺癌MRI动态增强模式与肿瘤血管生成的相关性研究.中华放射学杂志.2002,37,1150-1155.
16 Buadu LD,Murakami J,Murayama S,et al.Patterns of peripheral enhancement in breast masses:correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis.J Comput Assist Tomogr,1997,21:421-430.
17 Heywang-Kobrunner SH,Bick U,Bradley WG Jr,et al.International investigation of breast MRI:results of a multicentre study(11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions.Eur Radiol,2001,11:531-546.
18 Tofts PS,Brix G,Buckley DL,et al.Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer:standardized quantities and symbols.J Magn Reson Imaging,1999,10:223-232.
19 Tse GM,Chaiwun B,Wong KT,et al.Magnetic resonance imaging of breast lesions-a pathologic correlation.Breast Cancer Res Treat,2007,103:1-10.
1 陈蓉,龚水根,张伟国等.乳腺癌MRI形态学表现与病理、分子生物学相关性研究.中华放射学杂志,2004,38:620-625.
2 Tozaki M.Interpretation of breast MRI:correlation of kinetic and morphological parameters with pathological fingdings.Magnetic Resonance in Medical Sciences,2004,3:189-197.
3 Schnall MD,Rosten S,Englander S,et al.A combined architectural and kinetic interpretation model for breast MR images.Acad Radio,2001,8(7):591-597.
4 Kuhl CK,Mielcareck P,Klaschik S et al.Dynamic breast MR imaging:are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology,1999,211(1):101-110.
5 Stephen s.Steinberg主编,外科病理学,回允中主译。北京大学医学出版社,2006.1。Frierson HF,Jr,Wolber RA,Berean KW,et al.Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma.Am J Clin Pathol 1995;103(2):195-198.
7 Neubauer H,Mengxia LI,Kuehne HR,et al.High grade and nonhigh grade ductal carcinoma in situ on dynamic MR mamography:characteristic findings for signal increase and morphological pattern of enhancement.B r J Radiol,2003,76:3-12.
8 Teifke A,Lehr HA,Vomweg TW,et al.Outcome analysis and rational management of enhancing lesions incidentally detected on contrast enhanced MRI of the breast.AJR,2003,181(3):655-662.
9 LaTrenta LR,Jennifer H,Menell EA,et al.Breast lesions detected with MR imaging:utility and histopathologic importance of identification with US.Radiology,2003,22 7(3):856-861.
10 Teifke A,Alexander H,Thomas B,et al.Undetected malignancies of the breast:dynamic contrast-enhanced MR imaging at 1.0T.Radiology,2002,224(3):881-888.
11 Fischer U,KopkaL,GrabbeE,et al.Breast carcinoma:effect of preoperative contrast-enhanced MR imaging on the therapeutic approach.Radiology,1999,213(3):881-888.
12 Kneeshaw PI,TurnbullL W,Smith A,et al.Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer.EJSO,2003,29(1):32-37.
13 Rieber A,Katharina S,Gisela H,et al.Breast-conserving surgery and autogenous tissue reconstruction in patients with breast cancer:efficacy of MRI of the breast in the detection of recurrent disease.Eur Radiol,2003,13(4):780-787.
14 Morris EA,Liberman L,Douglas BJ,et al.MRI of occult breast carcinoma in a high-risk population. AJR, 2003,181(3):619-626.
15 Orel SG MR imaging of the breast. Radiol Clin North Am, 2000, 38(4):899-913.
16 Kuhl CK. MRI of breast tumor. Eur Radiol, 2000,10(1):46-58.
17 Esserman L, Hylton N, George T, et al. Contrast-enhanced Magnetic Resonance Imaging to assess Tumor Histopathology and Angiogenesis in Breast Carcinoma[J]. Breast J, 1999, 5(1): 13-21.
18 Carriero A, Ambrossini R, Mattei PA,et al. Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors. J Exp Clin Cancer Res, 2002, 21(3 Suppl):83-87.
19 Tuncbilek N, Unln E, Karakas HM, et al. Evaluation of tumor angiogenesis with contrast enhanced dynamic magnetic resonance mammography[J]. Breast J, 2003, 9(5):403-408.
20 Tynninen O, Boguslawski KV, Aronen HJ, et al. Prognostic value of vascular density and cell proliferation in breast cancer patients. Pathol Res Pract, 1999, 195:31-37.
21 Bando H, Weich HA, Brokelmann M, et al. Association between in tratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer, 2005, 92(3):553-61.
22 Francisco JE,Gabriel NH.Prognostic molecular markers in early breast cancer. Breast Cancer Res, 2004,6(3): 109-118.
23 Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol, 1995,104(1):42-49.
24 Paik S , Bryant J , Park C , et al .C-erbB-2 and response to doxorubicin in patients with axillary lymph node positive , hormone receptor negative breast cancer[J] . J Natl Cancer Inst, 1998 , 90 (18): 1361 - 1370.
25 Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer, 2005, 5(8):591-602.
26 Broet P, Spyratos F, Romain S, et al.Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. Br J Cancer, 1999,80(3-4):536-545.
27 Harbeck N,Kates RE,Schmitt M.Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol, 2002,20(4): 1000-1007.
28 Michael J. Duffy.Urokinase Plasminogen Activator and Its Inhibitor,PAl-l, as Prognostic Markers in Breast Cancer : From Pilot to Level 1 Evidence Studies. Clinical Chemistry, 2002,48(8): 1194-1197.
29 Stomper PC, Herman S, Klippenstein DL.Suspect breast lesions:findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology, 1995,197:387-395
30 Schnall MD.An overview of interpretation strategies for breast MR imaging. Magn Reson Imaging Clin Nam, 2001,9(2):289-294.
31 Nunes LW,SCHnall MD,Orel SG,et al.Breast MR imaging: interpretation model.Radiology, 1997,202(3):833-841.
32 Buadu LD,Murakami J,Murayama S,et al.Breast lesionsxorrelation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis.Radiology, 1996,200(3):639-649.
33 Buckley DL,Drew PJ,Mussurakis S,et al.Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI.J Magn Reson Imaging , 1997,7:461-464.
34 Matsubayashi R,Matsuo Y,Edakuni G, et al. Breast masses with peripheral rim enhancement on dynamic contrast enhanced MR images:correlation of MR findings with histologic features and expression of growth factors. Radiology ,2000,217(3):841-848.
35 Stamper PC, Herman S, Klippenstein DL,et al.Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer, 1996,77(9): 1844-1849.
36 Szabo BK, Aspelin P, Kristoffersen Wiberg M, et al.Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol, 2003,13(11):2425 - 2435.
37 Tuncbilek N, Karakas HM, Okten OO. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol, 2005,53 (2): 199-205.
38 Lamb PM,Perry NM,Vinnicombe SJ,et al.Correlation between ultrasound characteristics,mammographic findings and histological grade in patients with invasive ductal carcinoma of the breast.Clin Radio,2000,55:40-44
39 Fischer U, Kopka L, Brinck U, et al.Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol, 1997 ,7(7): 1002-1005.
40 Bone B, Aspelin P, Bronge L, et al. Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol, 1998 ,39:279-84.
41 Mussrakis S,Buckley DL,Horsman A. Dynamic MR imaging of invasive breast cancer: correlation with tumor grade and other histological factors. Br J Radiol, 1997,70(833): 445-46.
[42] 李明山,周玉荣,王丽等. 3D TIWI 动态增强成像诊断乳腺良恶性病变的价值. 中国临床医学影像杂志. 2005, 5 (16): 256-259
1. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res, 1991, 51(18 Suppl):5054-5059
2. Hulka CA, Edmister WB, Smith BL, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology, 1997,205(3): 837-842
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285(21):1182— 1186
4. Folkman J, Beckner K. Angiogenesis imaging. Acad Radiol, 2000,7( 10):783-785
5. Kolch W, Martiny-Baron G, Kieser A, et al. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat, 1995,36(2): 139-155
6. Kato T, Kimura T, Miyakawa R, et al. Clinicopathologic study of angiogenesis in Japanese patients with breast cancer. World J Surg, 1997,21(1):49-56
7. Orel SG. MR imaging of the breast. Radiol Clin North Am , 2000, 38:899-913.
8. Kuhl CK. MRI of breast tumor. Eur Radiol, 2000,10(1):46-58
9. Kuhl C, Mielcareck P, Klaschnik S, et al. Dynamik breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions. Radiology, 1999,211 (1) :101—110
10. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging,2003,18(4):467-477
11. Yoko Andoa, Hiroshi Fukatsua, Tsuneo Ishiguchia,et al. Diagnostic utility of tumor vascularity on magnetic resonance imaging of the breast. Magn Reson Imaging , 2000,18(7): 807-813
12. Stomper PC, Winston JS, Herman S, et al. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat, 1997, 45(1):39-46
13. Furuta A, Ishibashi T, Takahashi S, et al. Magnetic resonance imaging of breast cancer: correlation between contrast enhancement and tumor angiogenesis. Nippon Igaku Hoshasen Gakkai Zasshi,1999, 59(12):682-688
14. Furman-Haran E, Edna, Degani, et al. Parametric Analysis of Breast MRI. J Comput Assist Tomogr, 2002, 26(3):376-386
15. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1 -weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging, 1999, 10(3):223-232
16. Nagasima T,Suzuki M,Yagata H, et al. Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast cancer,2002, 9(3):226-230
17. Aref M, Brechbiel M, Wiener EC, et al. Identifying Tumor Vascular Permeability Heterogeneity With Magnetic Resonance Imaging Contrast Agents. Invest Radiol, 2002, 37(4): 178-192
18. Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging, 2004, 20(1):138-144
19. Daldrup-Link HE, Kaiser A, Helbich T, et al. Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. Acad Radiol, 2003, 10(11):1237-1246
20. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by alphaVbeta3- targeted magnetic resonance imaging. Nat Med, 1998,4: 623
1. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist,2004, 9(6): 606-616.
2. Jatoi I,Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol, 1999,17(8):2334-40.
3. Albertini JJ, Lyman GH, Cox C. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA, 1996,276(22): 1818-1822.
4. Chia SK, Speers CH, Bryce CJ, et al. Ten-Year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol,2004,22(9): 1630-1637.
5. Francisco JE,Gabriel NH. Prognostic molecular markers in early breast cancer. Breast Cancer Res, 2004,6(3): 109-118.
6. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol,1995,104(1):42-49.
7. Hilsenbeck SG, Ravdin PM, de Moor CA. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat, 1998,52(1-3):227 - 237.
8. Early Breast Cancer Trialists' Collaborative Group.Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 1998,351(9114): 1451 - 1467.
9. Harold J,Burstein. The distinctive nature of HER2-positive breast cancers. NEJM,2005, 353(16):1652-1654.
10. Schnall MD, Rosten S, Englander S,et al. A combined architectural and kinetic interpretation model for breast MR images. Acad Radiol ,2001,8(7):591 - 597.
11. Tuncbilek N,Karakas HM,Okten OO. MRI in multiple myeloma with orbitaland and dural invasion.Tumori,2005,91(3):270-272.
12. Szabo BK, Aspelin P, Kristoffersen Wiberg M,et al. Invasive breast cancer:correlation of dynamic MR features with prognostic factors.Eur Radiol, 2003,13(11):2425 - 2435.
13. Stomper PC, Herman S, Klippenstein DL, et al. Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer, 1996,77(9): 1844-1849.
14. Jinguji M, Kajiya Y, Kamimura K, et al. Rim enhancement of breast cancers on contrast-enhanced MR imaging: relationship with prognostic factors. Breast cancer (Tokyo, Japan) ,2006,13(1): 64-73.
15. Teifke A, Behr O, Schmidt M, et al. Dynamic MR Imaging of Breast Lesions: Correlation with Microvessel Distribution Pattern and Histologic Characteristics of Prognosis. Radiology 2006;239(2):351-360
16. Tozaki M.Interpretation of breast MRIxorrelation of kinetic and morphological parameters with pathological findings. Magn Reson Medi Sci ,2004,3(4): 189-197.
17. Kuhl CK, Mielcareck P, Klaschik S. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology, 1999,211(1): 101 - 110.
18. Tuncbilek N, Karakas HM, Okten OO. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol, 2005,53 (2): 199-205.
19. Komatsu S,Lee CJ, Ichikawa D et al. Predictive value of the time-intensity curves on dynamic contrast-enhanced magnetic resonance imaging for lymphatic spreading in breast cancer. Surg Today 2005,35(9): 720-724.
20. Mussrakis S, Buckley DL, Horsman A. Dynamic MR imaging of invasive breast cancerxorrelation with tumor grade and other histological factors. Br J Radiol ,1997,70(833): 446-45.
21. Mussrakis S, Buckley DL, Horsman A. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging. Radiology. 1997;203(2):317-21.
22. Bone B, Aspelin P, Bronge L, et al. Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol, 1998 ,39(3):279-84.
23. Stomper PC, Herman S, Klippenstein DL. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology, 1995,197(2):387-395
24. Fischer U, Kopka L, Brinck U, et al. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol ,1997 ,7(7): 1002-1005.
25. Kobayashi H, Kawamoto S. Sakai Y, et al. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst,2004,96(9):703-8.
26. Seenu V, Pavan Kumar MN, Sharma U, et al. Potential of magnetic resonance spectroscopy to detect metastasis in axillary lymph nodes in breast cancer. Magn Reson Imaging ,2005,23(10): 1005-1010.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |